Bowen disease
Squamous cell carcinoma IN SITU (intraepidermal)
Overview
Squamous cell carcinoma in situ — full-thickness epidermal dysplasia that has not yet breached the basement membrane. A slowly enlarging, well-demarcated, erythematous SCALY plaque, classically on the lower legs of older women. A small proportion progress to invasive SCC.
Recognise
- A slowly enlarging, well-demarcated, erythematous scaly or crusted plaque, often on the lower leg
- Flat (does not have the rolled edge of BCC or the nodularity of invasive SCC)
- Risk factors: chronic sun exposure, older age, immunosuppression, HPV, prior arsenic exposure
Red flags
- Development of a nodule, ulceration, or rapid growth within the plaque → progression to invasive SCC (biopsy)
Differentials & how to tell them apart
Clinical image
We can't host this one — the image is DermNet's and their licence doesn't cover us republishing it. Their page for it is free to view.
Investigations
Dermoscopy + biopsy (full-thickness epidermal atypia, intact basement membrane). Biopsy any nodular/ulcerated area to exclude invasive SCC.
Management
Topical 5-fluorouracil or imiquimod, cryotherapy, or PDT for the in-situ plaque
- 1Confirm with biopsy. Treat the in-situ plaque with topical 5-FU or imiquimod, cryotherapy, curettage or photodynamic therapy.Gate: A new nodule, induration or ulceration within a Bowen plaque signals progression to INVASIVE SCC → biopsy and excise rather than continuing topical field therapy
- 2Unresponsive, nodular, or diagnostically uncertain → surgical excision; surveillance for further keratinocyte cancers.
Key points
Bowen = SCC in situ; only a minority become invasive but a changing nodule must be biopsied. Lower legs of older women is the classic location (slow healing — choose treatment accordingly).
Monitor & prognosis
Response to field therapy; watch for invasive change.
Excellent; small risk of progression to invasive SCC.
Source: NICE CKS; BAD Bowen disease guideline